Related references
Note: Only part of the references are listed.Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer
Bairavi Shankar et al.
JAMA ONCOLOGY (2020)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
Francois-Xavier Danlos et al.
EUROPEAN JOURNAL OF CANCER (2018)
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
Gita Thanarajasingam et al.
LANCET HAEMATOLOGY (2018)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A. M. Menzies et al.
ANNALS OF ONCOLOGY (2017)
Share Paper
